1stOncology™: Cancer Intelligence Service – Page 13812 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting

On May 16, 2019 Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, reported that it will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research programme at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago on 3 June 2019 (Press release, Immunocore, MAY 16, 2019, View Source [SID1234536361]). Tebentafusp (IMCgp100) is a novel bispecific biologic T cell receptor therapy with an anti-CD3 immune-redirecting effector function and specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"At ASCO (Free ASCO Whitepaper), we will present clinical and biomarker data from our lead bispecific tebentafusp programme that provide insight into its mechanism of action," said David Berman, Head of Research and Development at Immunocore. "We believe these data will translate across our ImmTAC platform and provide another step towards identifying which patient populations benefit."

Poster discussion/poster: Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma (Abstract #9523, Poster #94)

Highlighting new mechanism of action results for tebentafusp (IMCgp100), this poster will be presented by Mark Middleton, MD, Head, Department of Oncology, University of Oxford, on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
The poster will also be discussed by Sophie Piperno-Neumann, MD, Department of Medical Oncology, Institut Curie, in the Melanoma/Skin Cancers poster discussion session on Monday 3 June, 4:30-6:00 p.m. CDT in Room E451.
Poster: Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma (Abstract #9530, Poster #101)

In a retrospective analysis, reporting the potential association of rash with overall survival and temporal association of key cytokines with cytokine mediated adverse events for tebentafusp (IMCgp100), this poster will be presented by Omid Hamid, MD, Chief of Translational Research and Immunotherapy and Director of Melanoma Therapeutics, Angeles Clinic, in the Melanoma/Skin Cancers poster session on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
Analyses presented at the meeting stemmed from a Phase 1 clinical trial assessing the safety and tolerability of tebentafusp (NCT01211262).

About Tebentafusp

Tebentafusp is a novel bispecific biologic T cell redirection therapy with an anti-CD3 immune-redirecting effector function that specifically targets the melanoma associated antigen gp100. It is now in pivotal studies for metastatic uveal melanoma. Tebentafusp has Fast Track Designation and Orphan Drug Designation in the US and Promising Innovative Medicine designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).

Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics

On May 15, 2019 Scintomics GmbH and 1717 Life Science Ventures GmbH reported to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher (Press release, Scintomics, MAY 15, 2019, View Source [SID1234561514]).

PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.

Interviews: "We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs", said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.

"The introduction of 68Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies", added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. "Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials."

About PentixaFor / PentixaTher

This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.

LIDDS completes a directed issue raising SEK 8.9 million

On May 15, 2019 The board of directors of LIDDS AB has reported to carry out a directed issue of 641.200 shares at a subscription price of SEK 13.85 per share (Press release, Lidds, MAY 15, 2019, View Source [SID1234555906]). LIDDS will through the directed share issue receive proceeds amounting to SEK 8.9 million, before transaction costs.

The board of directors of LIDDS has, based on the authorization given by the annual general meeting on May 16, 2018, decided to carry out a directed issue of 641.200 shares to Swedish and international investors.

The subscription price in the Directed Share Issue is set to SEK 13.85 and has been determined by closing market price on May 14, 2019. Through the Directed Share Issue, LIDDS will raise SEK 8.9 million before transaction costs. The subscription price in the Directed Share Issue constitutes no discount compared the closing price on 14 May 2019.

The Directed Share Issue entails a dilution of approximately 2.7 percent of the number of shares and the votes in the Company. Through the Directed Share Issue, the number of outstanding shares and votes will increase by 641,200 shares from 23,051,188 shares to 23,692,388 shares. The share capital will increase by SEK 33,983.60 from SEK 1,221,712.96 to SEK 1,255,696.56.

The reason for the deviation from the shareholders’ preferential rights, is to strengthen the shareholder base and to finance LIDDS’ exciting development projects. The Directed Share Issue will primarily be used to finance the NZ-TLR9 project including the Phase I clinical trial of the same proprietary drug candidate.

Subscribers in the Directed Share Issue are Wikow Invest, BWG Invest together with new and existing large shareholders.

Advisers
Advokatfirman Delphi is legal adviser in connection with the Directed Share Issue.

AnHeart Therapeutics completed 100 million Chinese Yuan Series A round of financing; new anti-cancer drugs to enter China’s clinical trials

On May 15, 2019 AnHeart Therapeutics (Hangzhou) Co., Ltd.. (hereinafter referred to as AnHeart) reported the completion of the series A round of financing raising about 100 million Chinese yuan (Press release, AnHeart Therapeutics, MAY 15, 2019, View Source [SID1234555758]). The financing was exclusively provided by Decheng Capital, an internationally known venture capital institution specializing in the biomedical industry. This round of financing will be used to establish the AnHeart team to carry out Phase 2 clinical trials of its leading asset AB-106 and to further enrich the company’s product pipeline.

AnHeart is a clinical stage company, specialized in acquisition, development and commercializing innovative drugs that improve human health and quality of life. Its leading asset is AB-106, an oral, highly selective ROS1/NTRK small molecule inhibitor. This new anticancer drug was acquired from Japan’s Daiichi Sankyo Co., Ltd. in December 2018.

Early clinical trials have shown that AB-106 had satisfactory safety and efficacy and exhibits long progression-free survival in patients with non-small cell lung cancer with ROS1 fusion mutations. Currently, AB-106 has completed phase 1 clinical trials in the United States and Japan for the treatment of patients with solid tumors and neuroendocrine tumors containing ROS1 or NTRK fusion genes. The latest Phase 1 clinical trial results are expected to be reported in detail at the China Clinical Oncology Association Annual Meeting (CSCO) in September 2019.

"AnHeart is committed to the development of innovative drugs with unmet clinical needs," said Dr. Wang Yuyuan, co-founder and CEO of AnHeart. "With the strong support from Decheng Capital, we successfully acquired worldwide global rights for AB-106 from Japan Daiichi Sankyo and took over the long-term follow-up of the product in the US IND and Phase 1 clinical trials." Strategic collaborations are one of the strategies of Anheart. The company plans to establish and enhance clinically innovative product pipelines with near key value inflection points by working with large and medium-sized biopharmaceutical companies."

Dr. Yan Bing, Co-Founder and CMO of Anheart added: "Our team has very rich clinical development experience, and successful drug approval experience in Asia Pacific, Europe and America. We also have long term collaboration with top industry leaders as well. In fact, leveraging our global clinical development capabilities and interdisciplinary expert networks to optimize the clinical commercial value of assets is another strategy of AnHeart."

"Besides acquiring clinical assets by cooperation with large and medium-sized biopharmaceutical projects, we also consider introducing and developing assets that have not entered the clinical phase but have demonstrated good potential in animal experiments in order to build and consolidate an innovative product pipeline", Dr. Zheng Lihua, Co-Founder and CBO of AnHeart added.

"We are very glad we have the opportunity to support Anheart", said Dr. Cui Xiangmin, Managing Partner of Decheng Capital. "AnHeart has built a very successful clinical development team. We believe that AnHeart can use its strength in clinical development to bring a variety of innovative drugs to the market to meet the clinical needs of patients."

MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

On May 15, 2019 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported that Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, 2019 at 11:30 am at the Beverly Hilton Hotel in Beverly Hills, California (Press release, MediciNova, MAY 15, 2019, View Source [SID1234536437]). MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley FBR